pirbuterol has been researched along with Cardiac Failure in 29 studies
pirbuterol: structure
| Excerpt | Relevance | Reference |
|---|---|---|
| "Fifty-nine patients with severe chronic heart failure were given pirbuterol, a beta agonist with vasodilator and positive inotropic properties." | 9.05 | Treatment of chronic heart failure with pirbuterol: acute haemodynamic responses. ( Canepa-Anson, R; Carnie, J; Dawson, JR; Kuan, P; Poole-Wilson, PA; Reuben, SR; Sutton, GC; Warnes, C; Whitaker, NH, 1981) |
| "In 20 patients with severe congestive heart failure (CHF), we studied the effects of the beta-adrenergic agonist pirbuterol compared to placebo in both an acute double-blind randomized trial and after long-term treatment." | 9.05 | Acute and long-term hemodynamic effects of oral pirbuterol in patients with chronic severe congestive heart failure: randomized double-blind trial. ( Beller, GA; Bishop, HL; Carabello, BA; Gheorghiade, M; Grunwald, AM; Olukotun, AY; Pamelia, FX; Sirowatka, J; Taylor, CR; Watson, DD, 1983) |
| "The metabolic, hormonal and haemodynamic effects of oral pirbuterol, a new beta 2-adrenoceptor agonist, were studied acutely (n = 19) and after 3 months treatment (n = 11) in patients with severe heart failure receiving chronic frusemide therapy." | 7.67 | Differences between acute and long-term metabolic and endocrine effects of oral beta-adrenoceptor agonist therapy with pirbuterol for cardiac failure. ( Canepa-Anson, R; Cockrill, B; Dawson, JR; Kuan, P; Poole-Wilson, PA; Reuben, SR; Sutton, GC, 1987) |
| "We compared the initial and long-term effects of the beta-adrenergic agonist pirbuterol in 12 patients with chronic congestive heart failure." | 7.66 | Decreased lymphocyte beta-adrenergic-receptor density in patients with heart failure and tolerance to the beta-adrenergic agonist pirbuterol. ( Alexander, RW; Braunwald, E; Colucci, WS; Holman, BL; Konstam, MA; Mudge, GH; Rude, RE; Williams, GH; Wynne, J, 1981) |
| "Fourteen patients with refractory congestive heart failure (CHF) were given a single oral dose ranging from 5 to 30 mg of the new sympathomimetic drug pirbuterol." | 7.66 | Pirbuterol: a new oral sympathomimetic amine for the treatment of congestive heart failure. ( Asinger, RW; Cohn, JN; Francis, GS; Hoback, J; Hodges, M; Sharma, B; Taylor, CR, 1981) |
| "An open study of long term treatment with an oral beta 2 agonist (pirbuterol 20 mg three times daily) was undertaken in 63 patients with severe chronic heart failure." | 7.66 | Symptoms, haemodynamics, and exercise capacity during long term treatment of chronic heart failure. Experience with pirbuterol. ( Canepa-Anson, R; Dawson, JR; Kuan, P; Poole-Wilson, PA; Reuben, SR; Sutton, GC, 1983) |
| "Pirbuterol hydrochloride, an orally effective beta-adrenergic agonist, improves hemodynamic abnormalities in patients with congestive heart failure, but its effects on myocardial oxygen consumption (MVO2) and coronary blood flow have not been characterized." | 7.66 | Acute effects of oral pirbuterol on myocardial oxygen metabolism and systemic hemodynamics in chronic congestive heart failure. ( Brown, EJ; Colucci, WS; Grossman, W; Lorell, BH; Mudge, GH; Rude, RE; Taylor, CR; Turi, Z, 1981) |
| " To assess the adequacy of 20 mg of PB, the dose-response relations of cardiocirculatory effects to 10, 15, 20 and 30 mg of PB were compared in seven of the above patients and nine other patients." | 6.65 | Pirbuterol, an oral beta-adrenergic receptor agonist, in the treatment of chronic cardiac failure. ( Andrews, V; Janicki, JS; Likoff, M; Reichek, N; Weber, KT, 1982) |
| "Oral amrinone or pirbuterol were given in random order to each of 13 patients, on successive days, and oral isosorbide dinitrate was added after two-and-a-half hours." | 6.65 | Acute haemodynamic comparison of amrinone and pirbuterol in chronic heart failure. Additional effects of isosorbide dinitrate. ( Bayliss, J; Canepa-Anson, R; Norell, M; Poole-Wilson, PA; Reuben, SR; Sutton, GC, 1983) |
| "The animal and human pharmacology of several new drugs (prazosin, trimazosin, pirbuterol, and carbazeran) useful in the treatment of congestive heart failure (CHF) is delineated in relation to the pharmacology of other agents employed for CHF management." | 6.15 | Comparative pharmacology and clinical efficacy of newer agents in treatment of heart failure. ( Baird, JR; Blackburn, KJ; Cambridge, D; Constantine, JW; Ghaly, MS; Hayden, ML; McIlhenny, HM; Moore, PF; Olukotun, AY; Pullman, LG; Salsburg, DS; Saxton, CA; Shevde, S; Taylor, CR, 1981) |
| "Fifty-nine patients with severe chronic heart failure were given pirbuterol, a beta agonist with vasodilator and positive inotropic properties." | 5.05 | Treatment of chronic heart failure with pirbuterol: acute haemodynamic responses. ( Canepa-Anson, R; Carnie, J; Dawson, JR; Kuan, P; Poole-Wilson, PA; Reuben, SR; Sutton, GC; Warnes, C; Whitaker, NH, 1981) |
| "In 20 patients with severe congestive heart failure (CHF), we studied the effects of the beta-adrenergic agonist pirbuterol compared to placebo in both an acute double-blind randomized trial and after long-term treatment." | 5.05 | Acute and long-term hemodynamic effects of oral pirbuterol in patients with chronic severe congestive heart failure: randomized double-blind trial. ( Beller, GA; Bishop, HL; Carabello, BA; Gheorghiade, M; Grunwald, AM; Olukotun, AY; Pamelia, FX; Sirowatka, J; Taylor, CR; Watson, DD, 1983) |
| "This study was designed to investigate and compare the haemodynamic and metabolic responses to pirbuterol and salbutamol in patients with congestive heart failure and coronary artery disease." | 5.05 | Potential value of oral beta 2-adrenoceptor agonists in congestive heart failure: a haemodynamic and metabolic study. ( Bergman, G; Jewitt, DE; Monaghan, MJ; Timmis, AD; Walker, L, 1984) |
| "The metabolic, hormonal and haemodynamic effects of oral pirbuterol, a new beta 2-adrenoceptor agonist, were studied acutely (n = 19) and after 3 months treatment (n = 11) in patients with severe heart failure receiving chronic frusemide therapy." | 3.67 | Differences between acute and long-term metabolic and endocrine effects of oral beta-adrenoceptor agonist therapy with pirbuterol for cardiac failure. ( Canepa-Anson, R; Cockrill, B; Dawson, JR; Kuan, P; Poole-Wilson, PA; Reuben, SR; Sutton, GC, 1987) |
| "We compared the initial and long-term effects of the beta-adrenergic agonist pirbuterol in 12 patients with chronic congestive heart failure." | 3.66 | Decreased lymphocyte beta-adrenergic-receptor density in patients with heart failure and tolerance to the beta-adrenergic agonist pirbuterol. ( Alexander, RW; Braunwald, E; Colucci, WS; Holman, BL; Konstam, MA; Mudge, GH; Rude, RE; Williams, GH; Wynne, J, 1981) |
| "Fourteen patients with refractory congestive heart failure (CHF) were given a single oral dose ranging from 5 to 30 mg of the new sympathomimetic drug pirbuterol." | 3.66 | Pirbuterol: a new oral sympathomimetic amine for the treatment of congestive heart failure. ( Asinger, RW; Cohn, JN; Francis, GS; Hoback, J; Hodges, M; Sharma, B; Taylor, CR, 1981) |
| "An open study of long term treatment with an oral beta 2 agonist (pirbuterol 20 mg three times daily) was undertaken in 63 patients with severe chronic heart failure." | 3.66 | Symptoms, haemodynamics, and exercise capacity during long term treatment of chronic heart failure. Experience with pirbuterol. ( Canepa-Anson, R; Dawson, JR; Kuan, P; Poole-Wilson, PA; Reuben, SR; Sutton, GC, 1983) |
| "Pirbuterol hydrochloride, an orally effective beta-adrenergic agonist, improves hemodynamic abnormalities in patients with congestive heart failure, but its effects on myocardial oxygen consumption (MVO2) and coronary blood flow have not been characterized." | 3.66 | Acute effects of oral pirbuterol on myocardial oxygen metabolism and systemic hemodynamics in chronic congestive heart failure. ( Brown, EJ; Colucci, WS; Grossman, W; Lorell, BH; Mudge, GH; Rude, RE; Taylor, CR; Turi, Z, 1981) |
| " To assess the adequacy of 20 mg of PB, the dose-response relations of cardiocirculatory effects to 10, 15, 20 and 30 mg of PB were compared in seven of the above patients and nine other patients." | 2.65 | Pirbuterol, an oral beta-adrenergic receptor agonist, in the treatment of chronic cardiac failure. ( Andrews, V; Janicki, JS; Likoff, M; Reichek, N; Weber, KT, 1982) |
| "Oral amrinone or pirbuterol were given in random order to each of 13 patients, on successive days, and oral isosorbide dinitrate was added after two-and-a-half hours." | 2.65 | Acute haemodynamic comparison of amrinone and pirbuterol in chronic heart failure. Additional effects of isosorbide dinitrate. ( Bayliss, J; Canepa-Anson, R; Norell, M; Poole-Wilson, PA; Reuben, SR; Sutton, GC, 1983) |
| "Amrinone appears to be a promising agent for the long-term treatment of chronic cardiac failure; the utility of pirbuterol, an oral catecholamine analog, remains to be determined." | 1.26 | Cardiotonic agents in the management of chronic cardiac failure. ( Andrews, V; Janicki, JS; Weber, KT, 1982) |
| "Modern management of congestive heart failure (CHF) employs inotropic drugs, vasodilators, and diuretics." | 1.26 | Problems in assessment of new pharmacologic agents for the heart failure patient. ( Benotti, JR; Braunwald, E; Carabello, BA; Colucci, WS; Grossman, W; Malacoff, R; Rude, RE; Wynne, J, 1981) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 29 (100.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Sharpe, DN | 1 |
| Dawson, JR | 6 |
| Canepa-Anson, R | 7 |
| Kuan, P | 6 |
| Whitaker, NH | 1 |
| Carnie, J | 1 |
| Warnes, C | 1 |
| Reuben, SR | 5 |
| Poole-Wilson, PA | 7 |
| Sutton, GC | 7 |
| Colucci, WS | 4 |
| Alexander, RW | 2 |
| Williams, GH | 1 |
| Rude, RE | 4 |
| Holman, BL | 2 |
| Konstam, MA | 1 |
| Wynne, J | 3 |
| Mudge, GH | 3 |
| Braunwald, E | 3 |
| Sharma, B | 1 |
| Hoback, J | 1 |
| Francis, GS | 1 |
| Hodges, M | 1 |
| Asinger, RW | 1 |
| Cohn, JN | 1 |
| Taylor, CR | 5 |
| Grossman, W | 3 |
| Warnes, CA | 1 |
| Gold, FL | 1 |
| Horwitz, LD | 1 |
| Weber, KT | 2 |
| Andrews, V | 2 |
| Janicki, JS | 2 |
| Likoff, M | 1 |
| Reichek, N | 1 |
| Bijak, A | 1 |
| Czołpiński, T | 1 |
| Frankl, WS | 1 |
| Reuben, S | 2 |
| Bayliss, J | 2 |
| Norell, MS | 1 |
| Smiseth, OA | 1 |
| Pamelia, FX | 1 |
| Gheorghiade, M | 1 |
| Beller, GA | 1 |
| Bishop, HL | 1 |
| Olukotun, AY | 2 |
| Watson, DD | 1 |
| Grunwald, AM | 1 |
| Sirowatka, J | 1 |
| Carabello, BA | 2 |
| Timmis, AD | 1 |
| Bergman, G | 1 |
| Walker, L | 1 |
| Monaghan, MJ | 1 |
| Jewitt, DE | 1 |
| Norell, M | 1 |
| Rae, AP | 1 |
| Tweddel, AC | 1 |
| Hutton, I | 1 |
| Awan, NA | 4 |
| Needham, K | 2 |
| Evenson, MK | 4 |
| Mason, DT | 4 |
| Baird, JR | 1 |
| Blackburn, KJ | 1 |
| Cambridge, D | 1 |
| Constantine, JW | 1 |
| Ghaly, MS | 1 |
| Hayden, ML | 1 |
| McIlhenny, HM | 1 |
| Moore, PF | 1 |
| Pullman, LG | 1 |
| Salsburg, DS | 1 |
| Saxton, CA | 1 |
| Shevde, S | 1 |
| Turi, Z | 1 |
| Brown, EJ | 1 |
| Lorell, BH | 1 |
| Hermanovich, J | 2 |
| Joye, JA | 1 |
| DeMaria, AN | 1 |
| Benotti, JR | 1 |
| Malacoff, R | 1 |
| Needham, KE | 2 |
| Evans, TO | 1 |
| Amsterdam, E | 1 |
| Vahanian, A | 1 |
| Le Potier, J | 1 |
| Sergent, J | 1 |
| Michel, PL | 1 |
| Acar, J | 1 |
| Uretsky, BF | 1 |
| Cockrill, B | 1 |
4 reviews available for pirbuterol and Cardiac Failure
| Article | Year |
|---|---|
Newer inotropic agents.
Topics: Aminopyridines; Amrinone; Cardiotonic Agents; Dobutamine; Ethanolamines; Heart Failure; Humans; Prac | 1984 |
[New drugs with positive inotropic action].
Topics: Adrenergic beta-Agonists; Albuterol; Aminopyridines; Amrinone; Cardiotonic Agents; Chronic Disease; | 1982 |
Beta 2 adrenoceptor agonists. Pharmacology, metabolic effects and arrhythmias.
Topics: Adrenergic beta-Agonists; Albuterol; Arrhythmias, Cardiac; Blood Glucose; Epinephrine; Ethanolamines | 1982 |
Comparative pharmacology and clinical efficacy of newer agents in treatment of heart failure.
Topics: Animals; Asthma; Carbamates; Cardiotonic Agents; Cardiovascular Agents; Clinical Trials as Topic; Dr | 1981 |
6 trials available for pirbuterol and Cardiac Failure
| Article | Year |
|---|---|
Treatment of chronic heart failure with pirbuterol: acute haemodynamic responses.
Topics: Administration, Oral; Adrenergic beta-Agonists; Adult; Aged; Chronic Disease; Ethanolamines; Female; | 1981 |
Pirbuterol, an oral beta-adrenergic receptor agonist, in the treatment of chronic cardiac failure.
Topics: Adrenergic beta-Agonists; Adult; Aged; Arrhythmias, Cardiac; Chronic Disease; Dose-Response Relation | 1982 |
Acute and long-term hemodynamic effects of oral pirbuterol in patients with chronic severe congestive heart failure: randomized double-blind trial.
Topics: Administration, Oral; Adult; Aged; Bronchodilator Agents; Chronic Disease; Clinical Trials as Topic; | 1983 |
Potential value of oral beta 2-adrenoceptor agonists in congestive heart failure: a haemodynamic and metabolic study.
Topics: Adult; Aged; Albuterol; Blood Glucose; Ethanolamines; Fatty Acids, Nonesterified; Female; Heart Fail | 1984 |
Acute haemodynamic comparison of amrinone and pirbuterol in chronic heart failure. Additional effects of isosorbide dinitrate.
Topics: Adult; Aged; Aminopyridines; Amrinone; Cardiotonic Agents; Chronic Disease; Drug Therapy, Combinatio | 1983 |
Comparative pharmacology and clinical efficacy of newer agents in treatment of heart failure.
Topics: Animals; Asthma; Carbamates; Cardiotonic Agents; Cardiovascular Agents; Clinical Trials as Topic; Dr | 1981 |
20 other studies available for pirbuterol and Cardiac Failure
| Article | Year |
|---|---|
Decreased lymphocyte beta-adrenergic-receptor density in patients with heart failure and tolerance to the beta-adrenergic agonist pirbuterol.
Topics: Adrenergic beta-Agonists; Adult; Aged; Blood Pressure; Chronic Disease; Drug Tolerance; Ethanolamine | 1981 |
Pirbuterol: a new oral sympathomimetic amine for the treatment of congestive heart failure.
Topics: Administration, Oral; Adrenergic beta-Agonists; Adult; Aged; Cardiotonic Agents; Dose-Response Relat | 1981 |
Acute and chronic effects of pirbuterol on left ventricular ejection fraction and clinical status in severe congestive heart failure.
Topics: Adrenergic beta-Agonists; Arrhythmias, Cardiac; Cardiac Output; Drug Evaluation; Ethanolamines; Hear | 1981 |
Single-dose and dose-response studies with oral pirbuterol, a new beta agonist in chronic heart failure.
Topics: Administration, Oral; Adrenergic beta-Agonists; Adult; Aged; Cardiotonic Agents; Dose-Response Relat | 1981 |
Hemodynamic effects of pirbuterol in conscious dogs.
Topics: Adrenergic beta-Agonists; Adrenergic beta-Antagonists; Animals; Cardiac Pacing, Artificial; Dogs; Et | 1981 |
Clinical studies with beta 2 adrenoceptor agonists in heart failure.
Topics: Adrenergic beta-Agonists; Albuterol; Aminopyridines; Amrinone; Cardiotonic Agents; Ethanolamines; He | 1982 |
Effects of the beta-adrenergic receptor agonist pirbuterol on cardiac performance during acute ischaemic left ventricular failure in dogs.
Topics: Adrenergic beta-Agonists; Animals; Blood Pressure; Coronary Disease; Dogs; Ethanolamines; Fatty Acid | 1983 |
Symptoms, haemodynamics, and exercise capacity during long term treatment of chronic heart failure. Experience with pirbuterol.
Topics: Adrenergic beta-Agonists; Adult; Aged; Cardiotonic Agents; Ethanolamines; Female; Heart Failure; Hem | 1983 |
Beta-agonists and heart failure.
Topics: Adrenergic beta-Agonists; Ethanolamines; Heart Failure; Hemodynamics; Humans | 1983 |
The clinical use of inotropes in cardiac failure: dopamine, dobutamine, prenalterol and pirbuterol.
Topics: Catecholamines; Dobutamine; Dopamine; Ethanolamines; Heart Failure; Hemodynamics; Humans; Practolol; | 1983 |
Management of severe chronic CHF with oral pirbuterol.
Topics: Cardiac Catheterization; Cardiac Output; Cardiotonic Agents; Chronic Disease; Ethanolamines; Heart F | 1981 |
Cardiotonic agents in the management of chronic cardiac failure.
Topics: Adult; Aged; Aminopyridines; Amrinone; Blood Pressure; Cardiac Output; Cardiotonic Agents; Dobutamin | 1982 |
Acute effects of oral pirbuterol on myocardial oxygen metabolism and systemic hemodynamics in chronic congestive heart failure.
Topics: Adult; Aged; Blood Pressure; Cardiac Output; Chronic Disease; Coronary Disease; Ethanolamines; Heart | 1981 |
Therapeutic efficacy or oral pirbuterol in severe chronic congestive heart failure: acute hemodynamic and long-term ambulatory evaluation.
Topics: Administration, Oral; Adult; Cardiotonic Agents; Dobutamine; Drug Evaluation; Drug Therapy, Combinat | 1981 |
Problems in assessment of new pharmacologic agents for the heart failure patient.
Topics: Aminopyridines; Amrinone; Cardiotonic Agents; Cardiovascular Agents; Drug Evaluation; Energy Metabol | 1981 |
Hemodynamic effects of oral pirbuterol in chronic severe congestive heart failure.
Topics: Adult; Aged; Blood Pressure; Cardiac Output; Cardiotonic Agents; Chronic Disease; Ethanolamines; Fem | 1981 |
Comparison of hemodynamic actions of pirbuterol and dobutamine on cardiac function in severe congestive heart failure.
Topics: Blood Pressure; Cardiac Output; Cardiotonic Agents; Catecholamines; Dobutamine; Ethanolamines; Femal | 1981 |
[Positive inotropic agents. Generalities and classification].
Topics: Adrenergic beta-Agonists; Aminopyridines; Amrinone; Calcium; Cardiotonic Agents; Digitalis Glycoside | 1985 |
Is inotropic therapy appropriate for patients with chronic congestive heart failure? Or is the digitalis leaf withering?
Topics: Amrinone; Cardiotonic Agents; Digoxin; Dobutamine; Enoximone; Ethanolamines; Heart; Heart Failure; H | 1986 |
Differences between acute and long-term metabolic and endocrine effects of oral beta-adrenoceptor agonist therapy with pirbuterol for cardiac failure.
Topics: Adult; Aged; Blood Glucose; Ethanolamines; Fasting; Fatty Acids, Nonesterified; Female; Heart Failur | 1987 |